<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34940980</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-3083</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Scandinavian journal of immunology</Title><ISOAbbreviation>Scand J Immunol</ISOAbbreviation></Journal><ArticleTitle>Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease.</ArticleTitle><Pagination><StartPage>e13101</StartPage><MedlinePgn>e13101</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e13101</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/sji.13101</ELocationID><Abstract><AbstractText>The coronavirus disease-19 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenged globally with its morbidity and mortality. A small percentage of affected patients (20%) progress into the second stage of the disease clinically presenting with severe or fatal involvement of lung, heart and vascular system, all contributing to multiple-organ failure. The so-called 'cytokines storm' is considered the pathogenic basis of severe disease and it is a target for treatment with corticosteroids, immunotherapies and intravenous immunoglobulin (IVIg). We provide an overview of the role of IVIg in the therapy of adult patients with COVID-19 disease. After discussing the possible underlying mechanisms of IVIg immunomodulation in COVID-19 disease, we review the studies in which IVIg was employed. Considering the latest evidence that show a link between new coronavirus and autoimmunity, we also discuss the use of IVIg in COVID-19 and anti-SARS-CoV-2 vaccination related autoimmune diseases and the post-COVID-19 syndrome. The benefit of high-dose IVIg is evident in almost all studies with a rapid response, a reduction in mortality and improved pulmonary function in critically ill COVID-19 patients. It seems that an early administration of IVIg is crucial for a successful outcome. Studies' limitations are represented by the small number of patients, the lack of control groups in some and the heterogeneity of included patients. IVIg treatment can reduce the stay in ICU and the demand for mechanical ventilation, thus contributing to attenuate the burden of the disease.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Scandinavian Journal of Immunology published by John Wiley &amp; Sons Ltd on behalf of The Scandinavian Foundation for Immunology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Danieli</LastName><ForeName>Maria Giovanna</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0002-9608-2252</Identifier><AffiliationInfo><Affiliation>Clinica Medica, Dipartimento di Medicina Interna, AOU Ospedali Riuniti di Ancona and DISCLIMO, Universit&#xe0; Politecnica delle Marche, Clinica Medica, Ancona, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Specialisation in Allergology and Clinical Immunology, Dipartimento di Medicina Interna, AOU Ospedali Riuniti di Ancona, Universit&#xe0; Politecnica delle Marche, Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piga</LastName><ForeName>Mario Andrea</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-8678-1650</Identifier><AffiliationInfo><Affiliation>School of Specialisation in Allergology and Clinical Immunology, Dipartimento di Medicina Interna, AOU Ospedali Riuniti di Ancona, Universit&#xe0; Politecnica delle Marche, Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paladini</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3269-9015</Identifier><AffiliationInfo><Affiliation>School of Specialisation in Internal Medicine, Dipartimento di Medicina Interna, AOU Ospedali Riuniti di Ancona, Universit&#xe0; Politecnica delle Marche, Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longhi</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9299-1849</Identifier><AffiliationInfo><Affiliation>Scuola di Medicina e Chirurgia, Alma Mater Studiorum, Universit&#xe0; degli Studi di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mezzanotte</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8854-5149</Identifier><AffiliationInfo><Affiliation>School of Specialisation in Internal Medicine, Dipartimento di Medicina Interna, AOU Ospedali Riuniti di Ancona, Universit&#xe0; Politecnica delle Marche, Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moroncini</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-0380-0105</Identifier><AffiliationInfo><Affiliation>Clinica Medica, Dipartimento di Medicina Interna, AOU Ospedali Riuniti di Ancona and DISCLIMO, Universit&#xe0; Politecnica delle Marche, Clinica Medica, Ancona, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Specialisation in Internal Medicine, Dipartimento di Medicina Interna, AOU Ospedali Riuniti di Ancona, Universit&#xe0; Politecnica delle Marche, Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoenfeld</LastName><ForeName>Yehuda</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2802-4090</Identifier><AffiliationInfo><Affiliation>Ariel University, Ariel, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Saint Petersburg State University, St. Petersburg, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Scand J Immunol</MedlineTA><NlmUniqueID>0323767</NlmUniqueID><ISSNLinking>0300-9475</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">COVID&#x2010;19 vaccination</Keyword><Keyword MajorTopicYN="N">Coronavirus disease&#x2010;19</Keyword><Keyword MajorTopicYN="N">Long&#x2010;COVID</Keyword><Keyword MajorTopicYN="N">Post&#x2010;COVID</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">immunomodulation</Keyword><Keyword MajorTopicYN="N">intravenous immunoglobulin</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>23</Day><Hour>12</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34940980</ArticleId><ArticleId IdType="pmc">PMC8646640</ArticleId><ArticleId IdType="doi">10.1111/sji.13101</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
WHO
WHO Coronavirus (COVID&#x2010;19) Dashboard. World Health Organization; 
2021. (https://covid19.who.int/
</Citation></Reference><Reference><Citation>Shoenfeld Y. Corona (COVID&#x2010;19) time musings: our involvement in COVID&#x2010;19 pathogenesis, diagnosis, treatment, and vaccine planning. Autoimmun Rev. 2020;19:102538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7131471</ArticleId><ArticleId IdType="pubmed">32268212</ArticleId></ArticleIdList></Reference><Reference><Citation>Shevel E. Conditions favouring increased COVID&#x2010;19 morbidity and mortality: their common denominator and treatment. Isr Med Assoc J. 2020;11:680.</Citation><ArticleIdList><ArticleId IdType="pubmed">33249786</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkova A, Kudlay D, Kudryavtsev I, Starshinova A, Yablonskiy P, Shoenfeld Y. Immunogenetic predictors of severe COVID&#x2010;19. Vaccines. 2021;9:211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8001669</ArticleId><ArticleId IdType="pubmed">33802310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryabkova VA, Churilov LP, Shoenfeld Y. COVID&#x2010;19 and ABO blood groups. Isr Med Assoc J. 2021;23:140&#x2010;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">33734622</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafarzadeh A, Jafarzadeh S, Nozari P, Mokhtari P, Nemati M. Lymphopenia an important immunological abnormality in patients with COVID&#x2010;19: possible mechanisms. Scand J Immunol. 2021;93(2):e12967.</Citation><ArticleIdList><ArticleId IdType="pubmed">32875598</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadl N, Ali E, Salem TZ. COVID&#x2010;19: risk factors associated with infectivity and severity. Scand J Immunol. 2021;93(6):e13039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8265317</ArticleId><ArticleId IdType="pubmed">33710663</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahan S, Segal G, Katz I, et al. Ferritin as a marker of severity in COVID&#x2010;19 patients: a fatal correlation. Isr Med Assoc J. 2020;22:428&#x2010;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">33236582</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruscitti P, Giacomelli R. Ferritin and severe COVID&#x2010;19, from clinical observations to pathogenic implications and therapeutic perspectives. Isr Med Assoc J. 2020;22:516&#x2010;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">33236586</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumann S, Kaiser A, Nicoletti F, et al. Immune&#x2010;modulating drug MP1032 with SARS&#x2010;CoV&#x2010;2 antiviral activity in vitro: a potential multi&#x2010;target approach for prevention and early intervention treatment of COVID&#x2010;19. Int J Mol Sci. 2020;21:8803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7699954</ArticleId><ArticleId IdType="pubmed">33233817</ArticleId></ArticleIdList></Reference><Reference><Citation>Anka AU, Tahir MI, Abubakar SD, et al. Coronavirus disease 2019 (COVID&#x2010;19): an overview of the immunopathology, serological diagnosis and management. Scand J Immunol. 2021;93(4):e12998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7744910</ArticleId><ArticleId IdType="pubmed">33190302</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta&#x2010;Ampudia Y, Monsalve DM, Rojas M, et al. COVID&#x2010;19 convalescent plasma composition and immunological effects in severe patients. J Autoimmun. 2021;118:102598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826092</ArticleId><ArticleId IdType="pubmed">33524876</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilardin L, Bayry J, Kaveri SV. Intravenous immunoglobulin as clinical immune&#x2010;modulating therapy. Can Med Assoc J. 2015;187:257&#x2010;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4347774</ArticleId><ArticleId IdType="pubmed">25667260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar D, Gauthami R, Bayry J, et al. Antibody therapy: from diphtheria to cancer, COVID&#x2010;19, and beyond. Monoclon Antib Immunodiagn Immunother. 2021;40:36&#x2010;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">33900819</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;nemann JD, Quast I, Dalakas MC. Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics. 2016;13:34&#x2010;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4720677</ArticleId><ArticleId IdType="pubmed">26400261</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler H, Kaveri S. How IvIg can mitigate Covid&#x2010;19 disease: a symmetrical immune network. Model Monoclon Antib Immunodiagn Immunother. 2021;40:17&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">33513050</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonam SR, Kaveri SV, Sakuntabhai A, et al. Adjunct immunotherapies for the management of severely Ill COVID&#x2010;19 patients. Review Cell Rep Med. 2020;1:100016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190525</ArticleId><ArticleId IdType="pubmed">32562483</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeotti C, Kaveri SV, Bayry J. Intravenous immunoglobulin immunotherapy for coronavirus disease&#x2010;19 (COVID&#x2010;19). Clin Transl Immunol. 2020;9:e1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7565103</ArticleId><ArticleId IdType="pubmed">33088506</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Cao W, Li T. High&#x2010;dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia: the known mechanisms and clinical effects. Front Immunol. 2020;11:1660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7372093</ArticleId><ArticleId IdType="pubmed">32760407</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeilzadeh A, Rostami S, Yeganeh PM, et al. Recent advances in antibody&#x2010;based immunotherapy strategies for COVID&#x2010;19. J Cell Biochem. 2021. 1&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8427040</ArticleId><ArticleId IdType="pubmed">34160093</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo XH, Zhu Y, Mao J, Du RC. T cell immunobiology and cytokine storm of COVID&#x2010;19. Scand J Immunol. 2021;93(3):e12989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645942</ArticleId><ArticleId IdType="pubmed">33113222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryabkova VA, Churilov LP, Shoenfeld Y. Influenza infection, SARS, MERS and COVID&#x2010;19: cytokine storm &#x2010; The common denominator and the lessons to be learned. Clin Immunol. 2021;223:108652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832378</ArticleId><ArticleId IdType="pubmed">33333256</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu ZL, Wang Y, Zhang J, et al. Pathological findings of COVID&#x2010;19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420&#x2010;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Yang XO. TH17 responses in cytokine storm of COVID&#x2010;19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53:368&#x2010;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156211</ArticleId><ArticleId IdType="pubmed">32205092</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddur MS, Vani J, Hegde P, Lacroix&#x2010;Desmazes S, Kaveri SV, Bayry J. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol. 2011;127:823&#x2010;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">21281961</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddur MS, Rabin M, Hegde P, et al. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain&#x2010;Barr&#xe9; syndrome patients. Immunol Res. 2014;60:320&#x2010;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">25391612</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddur MS, Kaveri SV, Bayry J. Circulating normal IgG as stimulator of regulatory T cells: lessons from intravenous immunoglobulin. Trends Immunol. 2017;38:789&#x2010;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">28916232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessel A, Ammuri H, Peri R, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol. 2007;179:5571&#x2010;5575.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911644</ArticleId></ArticleIdList></Reference><Reference><Citation>Tr&#xe9;panier P, Chabot D, Bazin R. Intravenous immunoglobulin modulates the expansion and cytotoxicity of CD8+ T cells. Immunology. 2014;141:233&#x2010;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904244</ArticleId><ArticleId IdType="pubmed">24128001</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Pottier L, Sapir T, Bendaoud B, et al. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci. 2007;1110:426&#x2010;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911457</ArticleId></ArticleIdList></Reference><Reference><Citation>Blank M, Shoenfeld Y. Sialic acid&#x2010;IVIg targeting CD22. Blood. 2010;116:1630&#x2010;1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">20829376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessel A, Peri R, Haj T, et al. IVIg attenuates TLR&#x2010;9 activation in B cells from SLE patients. J Clin Immunol. 2011;31:30&#x2010;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">20922561</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie M, Yunis J, Yao Y. High levels of soluble CD25 in COVID&#x2010;19 severity suggest a divergence between anti&#x2010;viral and pro&#x2010;inflammatory T&#x2010;cell responses. Clin Transl Immunol. 2021;10:e1251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883478</ArticleId><ArticleId IdType="pubmed">33614032</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda A, Morita H, Unno H, et al. Anti&#x2010;inflammatory effects of high&#x2010;dose IgG on TNF&#x2010;&#x3b1;&#x2010;activated human coronary artery endothelial cells. Eur J Immunol. 2012;42:2121&#x2010;2131.</Citation><ArticleIdList><ArticleId IdType="pubmed">22585560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozicky LK, Menzies SC, Zhao ZY, et al. IVIg and LPS Co&#x2010;stimulation induces IL&#x2010;10 production by human monocytes, which is compromised by an Fc&#x3b3;RIIA disease&#x2010;associated gene variant. Front Immunol. 2018;9:2676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6255983</ArticleId><ArticleId IdType="pubmed">30515163</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha C, Kothapalli P, Patil V, et al. Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages. Hum Vaccin Immunother. 2020;16:233&#x2010;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7062444</ArticleId><ArticleId IdType="pubmed">30945973</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjon AS, van Gent R, Jaadar H, et al. Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL&#x2010;4 and IL&#x2010;13 production. J Immunol. 2014;192:5625&#x2010;5634.</Citation><ArticleIdList><ArticleId IdType="pubmed">24808368</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnam A, Rambabu N, Das M, et al. Therapeutic normal IgG intravenous immunoglobulin activates Wnt&#x2010;&#x3b2;&#x2010;catenin pathway in dendritic cells. Commun Biol. 2020;3:96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055225</ArticleId><ArticleId IdType="pubmed">32132640</ArticleId></ArticleIdList></Reference><Reference><Citation>Spijkerman R, Jorritsma NKN, Bongers SH, et al. An increase in CD62L dim neutrophils precedes the development of pulmonary embolisms in COVID&#x2010;19 patients. Scand J Immunol. 2021;93(6):e13023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7995011</ArticleId><ArticleId IdType="pubmed">33482019</ArticleId></ArticleIdList></Reference><Reference><Citation>Graeter S, Simon HU, von Gunten S. Granulocyte death mediated by specific antibodies in intravenous immunoglobulin (IVIG). Pharmacol Res. 2020;154:104168.</Citation><ArticleIdList><ArticleId IdType="pubmed">30738127</ArticleId></ArticleIdList></Reference><Reference><Citation>Uozumi R, Iguchi R, Masuda S, et al. Pharmaceutical immunoglobulins reduce neutrophil extracellular trap formation and ameliorate the development of MPO&#x2010;ANCA&#x2010;associated vasculitis. Mod Rheumatol. 2020;30:544&#x2010;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">30932727</ArticleId></ArticleIdList></Reference><Reference><Citation>Papaserafeim M, Jandus P, Iancu Ferfoglia R, et al. Effect of intravenous IgG therapy on natural killer cell function related to Fc gamma receptor gene expression. J Allergy Clin Immunol. 2020;146:667&#x2010;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">32311389</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eeden C, Khan L, Osman MS, Cohen Tervaert JW. Natural killer cell dysfunction and its role in COVID&#x2010;19. Int J Mol Sci. 2020;21:6351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7503862</ArticleId><ArticleId IdType="pubmed">32883007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID&#x2010;19 patients. Cell Mol Immunol. 2020;17(5):533&#x2010;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7091858</ArticleId><ArticleId IdType="pubmed">32203188</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoepel W, Chen H&#x2010;J, Geyer CJ, et al. High titers and low fucosylation of early human anti&#x2010;SARS&#x2010;CoV&#x2010;2 IgG promote inflammation by alveolar macrophages. Sci Transl Med. 2021;13(596):eabf8654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8158960</ArticleId><ArticleId IdType="pubmed">33979301</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen MD, de Graaf EL, Sonneveld ME, et al. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID&#x2010;19 severity. Science. 2021;371(6532):eabc8378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919849</ArticleId><ArticleId IdType="pubmed">33361116</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeniji OS, Giron LB, Purwar M, et al. COVID&#x2010;19 severity is associated with differential antibody Fc&#x2010;mediated innate immune functions. MBio. 2021;12:e00281&#x2010;e321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092230</ArticleId><ArticleId IdType="pubmed">33879594</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Chen S, Gan ES, Ooi EE. Impact of immune enhancement on Covid&#x2010;19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine. 2020;55:102768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161485</ArticleId><ArticleId IdType="pubmed">32344202</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha C, Das M, Patil V, et al. Monomeric immunoglobulin a from plasma inhibits human Th17 responses in vitro independent of Fc&#x3b1;RI and DC&#x2010;SIGN. Front Immunol. 2017;8:275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349300</ArticleId><ArticleId IdType="pubmed">28352269</ArticleId></ArticleIdList></Reference><Reference><Citation>Domizi R, Adrario E, Damiani E et aI. IgM&#x2010;enriched immunoglobulins (Pentaglobin) may improve the microcirculation in sepsis: a pilot randomized trial. Ann Intensive Care 2019;9:135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6890901</ArticleId><ArticleId IdType="pubmed">31797105</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar&#x2010;Hari M, Spencer J, Sewell WA, Rowan KM, Singer M. Bench&#x2010;to&#x2010;bedside review: immunoglobulin therapy for sepsis&#x2014;biological plausibility from a critical care perspective. Crit Care. 2012;16:206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3584720</ArticleId><ArticleId IdType="pubmed">22424150</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez JM, Romero C, Gajardo R. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens. Immunotherapy. 2020;12:571&#x2010;576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7222542</ArticleId><ArticleId IdType="pubmed">32397847</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC, Bitzogli K, Alexopoulos H. Anti&#x2010;SARS&#x2010;CoV&#x2010;2 antibodies within IVIg preparations: cross&#x2010;reactivities with seasonal coronaviruses, natural autoimmunity, and therapeutic implications. Front Immunol. 2021;12:627285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7925824</ArticleId><ArticleId IdType="pubmed">33679770</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS&#x2010;CoV&#x2010;2 in humans. Science. 2020;370:1339&#x2010;1343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857411</ArticleId><ArticleId IdType="pubmed">33159009</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwaiger J, Karbiener M, Aberham C, Farcet MR, Kreil TR. No SARS&#x2010;CoV&#x2010;2 neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic. J Infect Dis. 2020;222:1960&#x2010;1964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7546122</ArticleId><ArticleId IdType="pubmed">32941626</ArticleId></ArticleIdList></Reference><Reference><Citation>Meidaninikjeh S, Sabouni N, Marzouni HZ, Bengar S, Khalili A, Jafari R. Monocytes and macrophages in COVID&#x2010;19: friends and foes. Life Sci. 2021;269:119010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834345</ArticleId><ArticleId IdType="pubmed">33454368</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention
. Emergency preparedness and response: multisystem inflammatory syndrome in children (MIS&#x2010;C) associated with coronavirus disease 2019 (COVID&#x2010;19). Published May 14, 2020. https://emergency.cdc.gov/han/2020/han00432.asp
</Citation></Reference><Reference><Citation>Riphagen S, Gomez X, Gonzalez&#x2010;Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID&#x2010;19 pandemic. Lancet. 2020;395:1607&#x2010;1608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204765</ArticleId><ArticleId IdType="pubmed">32386565</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng MH, Zhang S, Porritt RA, et al. Superantigenic character of an insert unique to SARS&#x2010;CoV&#x2010;2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc Natl Acad Sci USA. 2020;117:25254&#x2010;25262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7568239</ArticleId><ArticleId IdType="pubmed">32989130</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishi JI, Kanekura S, Takei S, et al. B cell epitope mapping of the bacterial superantigen staphylococcal enterotoxin B: the dominant epitope region recognized by intravenous IgG. J Immunol. 1997;158:247&#x2010;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">8977196</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao W, Liu X, Bai T, et al. High&#x2010;dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis 2020;7:ofaa102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111600</ArticleId><ArticleId IdType="pubmed">32258207</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao Z, Feng Y, Zhong L, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID&#x2010;19: a multicentre retrospective cohort study. Clin Transl Immunol. 2020;9:e1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7557105</ArticleId><ArticleId IdType="pubmed">33082954</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Cao S, Dong H, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID&#x2010;19. J Infect. 2020;81:318&#x2010;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151471</ArticleId><ArticleId IdType="pubmed">32283154</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohtadi N, Ghaysouri A, Shirazi S, et al. Recovery of severely ill COVID&#x2010;19 patients by intravenous immunoglobulin (IVIG) treatment: a case series. Virology. 2020;548:1&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7247490</ArticleId><ArticleId IdType="pubmed">32530808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanza M, Polistina GE, Imitazione P, et al. Successful intravenous immunoglobulin treatment in severe COVID&#x2010;19 pneumonia. IDCases. 2020;21:e00794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7229478</ArticleId><ArticleId IdType="pubmed">32426229</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Jiang D, Xie SM, et al. Low&#x2010;dose corticosteroid combined with immunoglobulin reverses deterioration in severe cases with COVID&#x2010;19. Signal Transduct Target Ther. 2020;5:276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7683873</ArticleId><ArticleId IdType="pubmed">33235253</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao W, Liu X, Hong K, et al. High&#x2010;dose intravenous immunoglobulin in severe coronavirus disease 2019: a multicenter retrospective study in China. Front Immunol. 2021;12:627844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7933558</ArticleId><ArticleId IdType="pubmed">33679771</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine S, Dhakal GP, Penjor T, et al. Case report: the first case of COVID&#x2010;19 in Bhutan. Am J Trop Med Hyg. 2020;102(6):1205&#x2010;1207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7253094</ArticleId><ArticleId IdType="pubmed">32314685</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakoulas G, Geriak M, Kullar R, et al. Intravenous immunoglobulin (IVIG) significantly reduces respiratory morbidity in COVID&#x2010;19 pneumonia: a prospective randomized trial. MedRxiv 2020;2020.07.20.20157891.</Citation></Reference><Reference><Citation>Esen F, &#xd6;zcan PE, Orhum G, et al. Effects of adjunct treatment with intravenous immunoglobulins on the course of severe COVID&#x2010;19: results from a retrospective cohort study. Curr Med Res Opin. 2021;37:543&#x2010;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">33236646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zantah M, Castillo ED, Gangemi AJ, et al. Anakinra and intravenous IgG versus tocilizumab in the treatment of COVID&#x2010;19 pneumonia. MedRxiv. 2020;2020.09.11.20192401.</Citation></Reference><Reference><Citation>Tabarsi P, Barati S, Jamaati H, et al. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID&#x2010;19 cases: a randomized controlled trial. Int Immunopharmacol. 2021;90:107205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665876</ArticleId><ArticleId IdType="pubmed">33214093</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou X, Tian L, Zhou L, et al. Intravenous immunoglobulin&#x2010;based adjuvant therapy for severe COVID&#x2010;19: a single&#x2010;center retrospective cohort study. Virol J. 2021;18:101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139546</ArticleId><ArticleId IdType="pubmed">34020680</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharebaghi N, Nejadrahim R, Mousavi SJ, Sadat&#x2010;Ebrahimi SR, Hajizadeh R. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo&#x2010;controlled double&#x2010;blind clinical trial. BMC Infect Dis. 2020;20:786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7576972</ArticleId><ArticleId IdType="pubmed">33087047</ArticleId></ArticleIdList></Reference><Reference><Citation>Omma A, Erden A, Arma&#x11f;an B, et al. A single center experience of intravenous immunoglobulin treatment in Covid&#x2010;19. Int Immunopharmacol. 2021;98:107891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8200303</ArticleId><ArticleId IdType="pubmed">34153671</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Chen Y, Li R, et al. Intravenous immunoglobulin treatment for patients with severe COVID&#x2010;19: a retrospective multi&#x2010;center study. Clin Microbiol Infect. 2021:S1198&#x2013;743X(21),00234&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8131555</ArticleId><ArticleId IdType="pubmed">34020032</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang H&#x2010;R, Cheng X, Li Y, et al. Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID&#x2010;19): a meta&#x2010;analysis. Int Immunopharmacol. 2019;2021(96):107732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084608</ArticleId><ArticleId IdType="pubmed">34162133</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Fei L, Li W, et al. Efficacy evaluation of intravenous immunoglobulin in non&#x2010;severe patients with COVID&#x2010;19: A retrospective cohort study based on propensity score matching. Int J Infect Dis. 2021;105:525&#x2010;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833031</ArticleId><ArticleId IdType="pubmed">33434674</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman RS, Bhagwan Barge V, Anil Kumar D, et al. A Phase II safety and efficacy study on prognosis of moderate pneumonia in Coronavirus disease 2019 patients with regular intravenous Immunoglobulin therapy. J Infect Dis. 2021;223:1538&#x2010;1543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928808</ArticleId><ArticleId IdType="pubmed">33585890</ArticleId></ArticleIdList></Reference><Reference><Citation>Herth FJF, Sakoulas G, Haddad F. Use of intravenous immunoglobulin (Prevagen or Octagam) for the treatment of COVID&#x2010;19: retrospective case series. Respiration. 2020;99:1145&#x2010;1153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7801971</ArticleId><ArticleId IdType="pubmed">33316806</ArticleId></ArticleIdList></Reference><Reference><Citation>Spicer AJ, Jalkanen S. Why haven&#x2019;t we found an effective treatment for COVID&#x2010;19? Front Immunol. 2021;12:644850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8044372</ArticleId><ArticleId IdType="pubmed">33868280</ArticleId></ArticleIdList></Reference><Reference><Citation>Moradimajd P, Samaee H, Sedigh&#x2010;Maroufi S, Kourosh&#x2010;Aami M, Mohsenzadagan M. Administration of intravenous immunoglobulin in the treatment of COVID&#x2010;19: a review of available evidence. J Med Virol. 2021;93(5):2675&#x2010;2682.</Citation><ArticleIdList><ArticleId IdType="pubmed">33314173</ArticleId></ArticleIdList></Reference><Reference><Citation>Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin (IVIG) adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29:173&#x2010;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">16391392</ArticleId></ArticleIdList></Reference><Reference><Citation>Shemer A, Kivity S, Shoenfeld Y. Clinical indications for intravenous immunoglobulin utilization in a tertiary medical center: a 9&#x2010;year retrospective study. Transfusion. 2018;58:430&#x2010;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">29193136</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandman&#x2010;Goddard G, Krauthammer A, Levy Y, Langevitz P, Shoenfeld Y. Long&#x2010;term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol. 2012;42:247&#x2010;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">21732045</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalem D, Shemer A, Shovman O, Shoenfeld Y, Kivity S. The Efficacy of Intravenous Immunoglobulin in Guillain&#x2010;Barr&#xe9; Syndrome: The Experience of a Tertiary Medical Center. Isr Med Assoc J. 2018;20:754&#x2010;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">30550005</ArticleId></ArticleIdList></Reference><Reference><Citation>Danieli MG, Gelardi C, Pedini V, Menghini D, Benfaremo D, Gabrielli A. Subcutaneous immunoglobulin in inflammatory myopathies: efficacy in different organ systems. Autoimmun Rev. 2020;19:102426.</Citation><ArticleIdList><ArticleId IdType="pubmed">31734407</ArticleId></ArticleIdList></Reference><Reference><Citation>Danieli MG, Gelardi C, Pedini V, Moretti R, Gabrielli A, Logullo F. Subcutaneous IgG in immune&#x2010;mediate diseases: proposed mechanisms of action and literature review. Autoimmun Rev. 2014;13:1182&#x2010;1188.</Citation><ArticleIdList><ArticleId IdType="pubmed">25172241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;rin P, Pindi Sala T, Clerson P, et al. Recovering autonomy is a key advantage of home&#x2010;based immunoglobulin therapy in patients with myositis: a qualitative research study. Medicine. 2020;99:e19012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035045</ArticleId><ArticleId IdType="pubmed">32049796</ArticleId></ArticleIdList></Reference><Reference><Citation>Danieli MG, Menghini D, Mezzanotte C, Gelardi C, Pedini V, Monteforte F. High&#x2010;dose facilitated subcutaneous immunoglobulin in a patient with refractory polymyositis and severe interstitial lung disease. Isr Med Assoc J. 2019;21:494&#x2010;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">31507128</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenfeld M, Tincani A, Andreoli L, et al. Covid&#x2010;19 and autoimmunity. Autoimmun Rev. 2020;19:102597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289100</ArticleId><ArticleId IdType="pubmed">32535093</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang KT, Hsu BC, Chen DY. Autoimmune and rheumatic manifestations associated with COVID&#x2010;19 in adults: an updated systematic review. Front Immunol. 2021;12:645013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7994612</ArticleId><ArticleId IdType="pubmed">33777042</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpert G, Shoenfeld Y. SARS&#x2010;CoV&#x2010;2, the autoimmune virus. Autoimmun Rev. 2020;19:102695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598743</ArticleId><ArticleId IdType="pubmed">33130000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanduc D, Shoenfeld Y. On the molecular determinants of the SARS&#x2010;CoV&#x2010;2 attack. Clin Immunol. 2020;215:108426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165084</ArticleId><ArticleId IdType="pubmed">32311462</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS&#x2010;CoV&#x2010;2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20:102792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Han T, Chen J, et al. Clinical and autoimmune characteristics of severe and critical cases of COVID&#x2010;19. Clin Transl Sci. 2020;13:1077&#x2010;1086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan P, Dexhiemer T, Neubig RR, Uhal BD. COVID&#x2010;19&#x2010;A theory of autoimmunity against ACE&#x2010;2 explained. Front Immunol. 2021;12:582166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8021777</ArticleId><ArticleId IdType="pubmed">33833750</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Lim WS &amp; Emberson J, et al. RECOVERY Collaborative Group . Dexamethasone in Hospitalized Patients with Covid&#x2010;19. N Engl J Med. 2021;384:693&#x2010;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson E. RECOVERY trial: the UK covid&#x2010;19 study resetting expectations for clinical trials. BMJ. 2020;369:m1626.</Citation><ArticleIdList><ArticleId IdType="pubmed">32345591</ArticleId></ArticleIdList></Reference><Reference><Citation>Assini A, Benedetti L, Di Maio S, Schirinzi E, Del Sette M. New clinical manifestation of COVID&#x2010;19 related Guillain&#x2010;Barr&#xe9; syndrome highly responsive to intravenous immunoglobulins: two Italian cases. Neurol Sci. 2020;41:1657&#x2010;1658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8849645</ArticleId><ArticleId IdType="pubmed">32468450</ArticleId></ArticleIdList></Reference><Reference><Citation>Farzi MA, Ayromlou H, Jahanbakhsh N, Bavil PH, Janzadeh A, Shayan FK. Guillain&#x2010;Barr&#xe9; syndrome in a patient infected with SARS&#x2010;CoV&#x2010;2, a case report. J Neuroimmunol. 2020;346:577294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305747</ArticleId><ArticleId IdType="pubmed">32590125</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC. Guillain&#x2010;Barr&#xe9; syndrome: the first documented COVID&#x2010;19&#x2010;triggered autoimmune neurologic disease: more to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm. 2020;7:e781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309518</ArticleId><ArticleId IdType="pubmed">32518172</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchibori A, Gyohda A, Chiba A. Ca(2+)&#x2010;dependent anti&#x2010;GQ1b antibody in GQ1b&#x2010;seronegative Fisher syndrome and related disorders. J Neuroimmunol. 2016;298:172&#x2010;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">27609292</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara T, Yamamura K, Sakai Y. The up&#x2010;to&#x2010;date pathophysiology of Kawasaki disease. Clin Transl Immunol. 2021;10:e1284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8109476</ArticleId><ArticleId IdType="pubmed">33981434</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones VG, Mills M, Suarez D, et al. COVID&#x2010;19 and Kawasaki Disease: novel virus and novel case. Hosp Pediatr. 2020;10:537&#x2010;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">32265235</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki&#x2010;like disease at the Italian epicentre of the SARS&#x2010;CoV&#x2010;2 epidemic: an observational cohort study. Lancet. 2020;395:1771&#x2010;1778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7220177</ArticleId><ArticleId IdType="pubmed">32410760</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiotos K, Bassiri H, Behrens EM, et al. Multisystem inflammatory syndrome in children during the Coronavirus 2019 pandemic: a case series. J Pediatric Infect Dis Soc. 2020;9:393&#x2010;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7313950</ArticleId><ArticleId IdType="pubmed">32463092</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouletty M, Borocco C, Ouldali N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS&#x2010;CoV&#x2010;2 mimicking Kawasaki disease (Kawa&#x2010;COVID&#x2010;19): a multicentre cohort. Ann Rheum Dis. 2020;79:999&#x2010;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299653</ArticleId><ArticleId IdType="pubmed">32527868</ArticleId></ArticleIdList></Reference><Reference><Citation>Raahimi MM, Kane A, Moore CE, Alareed AW. Late onset of Guillain&#x2010;Barr&#xe9; syndrome following SARS&#x2010;CoV&#x2010;2 infection: part of 'long COVID&#x2010;19 syndrome'? BMJ Case Rep. 2021;14:e240178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7813388</ArticleId><ArticleId IdType="pubmed">33462068</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno&#x2010;P&#xe9;rez O, Merino E, Leon&#x2010;Ramirez JM, et al. for COVID19&#x2010;ALC research group. Post&#x2010;acute COVID&#x2010;19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect. 2021;82:378&#x2010;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Demir NA, Basturk A, Ural O, et al. A case of Evans syndrome secondary to COVID&#x2010;19. Blood Transfus. 2021;19:85&#x2010;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7850926</ArticleId><ArticleId IdType="pubmed">33263526</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmas &#xd6;F, Demirba&#x15f; A, T&#xfc;rsen &#xdc;, Atasoy M, Lotti T. Pemphigus and COVID&#x2010;19: critical overview of management with a focus on treatment choice. Dermatol Ther. 2020;33:e14265.</Citation><ArticleIdList><ArticleId IdType="pubmed">32882079</ArticleId></ArticleIdList></Reference><Reference><Citation>Rein N, Haham N, Orenbuch&#x2010;Harroch E, et al. Description of 3 patients with myasthenia gravis and COVID&#x2010;19. J Neurol Sci. 2020;417:117053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832365</ArticleId><ArticleId IdType="pubmed">32731059</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID&#x2010;19: a systematic review. SN Compr Clin Med. 2020;19:1&#x2010;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7501509</ArticleId><ArticleId IdType="pubmed">32984764</ArticleId></ArticleIdList></Reference><Reference><Citation>Novi G, Rossi T, Pedemonte E, et al. Acute disseminated encephalomyelitis after SARS&#x2010;CoV&#x2010;2 infection. Neurol Neuroimmunol Neuroinflamm. 2020;7:e797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286650</ArticleId><ArticleId IdType="pubmed">32482781</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad F, Ahmed A, Rajendraprasad SS, et al. Multisystem inflammatory syndrome in adults: a rare sequela of SARS&#x2010;CoV&#x2010;2 infection. Int J Infect Dis. 2021;108:209&#x2010;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8142712</ArticleId><ArticleId IdType="pubmed">34044140</ArticleId></ArticleIdList></Reference><Reference><Citation>Shemer A, Pras E, Hecht I. Peripheral facial nerve palsy following BNT162b2 (COVID&#x2010;19) vaccination. Isr Med Assoc J. 2021;23:143&#x2010;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">33734623</ArticleId></ArticleIdList></Reference><Reference><Citation>Watad A, De Marco G, Mahajna H, et al. Immune&#x2010;mediated disease flares or new&#x2010;onset disease in 27 subjects following mRNA/DNA SARS&#x2010;CoV&#x2010;2 vaccination. Vaccines. 2021;9:435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146571</ArticleId><ArticleId IdType="pubmed">33946748</ArticleId></ArticleIdList></Reference><Reference><Citation>Bril F, Al Diffalha S, Dean M, Fettig DM. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID&#x2010;19) vaccine: causality or casualty? J Hepatol. 2021;75:222&#x2010;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056822</ArticleId><ArticleId IdType="pubmed">33862041</ArticleId></ArticleIdList></Reference><Reference><Citation>Cines DB, Bussel JB. SARS&#x2010;CoV&#x2010;2 vaccine&#x2010;induced immune thrombotic thrombocytopenia. N Engl J Med. 2021;384:2254&#x2010;2256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8063912</ArticleId><ArticleId IdType="pubmed">33861524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E&#x2010;J, Cines DB, Gernsheimer T, et al. Thrombocytopenia following Pfizer and Moderna SARS&#x2010;CoV&#x2010;2 vaccination. Am J Hematol. 2021;96:534&#x2010;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014568</ArticleId><ArticleId IdType="pubmed">33606296</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SU, Khurram R, Lakhani A, Quirk B. Guillain&#x2010;Barr&#xe9; syndrome following the first dose of the chimpanzee adenovirus&#x2010;vectored COVID&#x2010;19 vaccine, ChAdOx1. BMJ Case Rep. 2021;14:e242956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8070856</ArticleId><ArticleId IdType="pubmed">33888484</ArticleId></ArticleIdList></Reference><Reference><Citation>Graf T, Thiele T, Klingebiel R, Greinacher A, Sch&#xe4;bitz WR, Greeve I. Immediate high&#x2010;dose intravenous immunoglobulins followed by direct thrombin&#x2010;inhibitor treatment is crucial for survival in Sars&#x2010;Covid&#x2010;19&#x2010;adenoviral vector vaccine&#x2010;induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. J Neurol. 2021;22:1&#x2010;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8140563</ArticleId><ArticleId IdType="pubmed">34023956</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabih HK. Importance of immunoglobulin therapy for COVID&#x2010;19 patients with lymphocytopenia. Bull Natl Res Cent. 2021;45:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7897881</ArticleId><ArticleId IdType="pubmed">33642851</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>